{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prodromal+Alzheimer%27s+Disease&page=2", "query": { "condition": "Prodromal Alzheimer's Disease", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prodromal+Alzheimer%27s+Disease&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T08:15:20.259Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03443973", "title": "Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 975, "start_date": "2018-08-22", "completion_date": "2022-11-28", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03443973" }, { "nct_id": "NCT04566003", "title": "Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease (AD)" ], "interventions": [ { "name": "[18F]GTP1", "type": "DRUG" }, { "name": "[18F]PI-2620", "type": "DRUG" }, { "name": "[18F]MK-6240", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 40, "start_date": "2020-10-26", "completion_date": "2023-06-27", "has_results": false, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566003" }, { "nct_id": "NCT02547818", "title": "Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "ALZT-OP1a", "type": "DRUG" }, { "name": "ALZT-OP1b", "type": "DRUG" }, { "name": "Placebo ALZT-OP1a", "type": "OTHER" }, { "name": "Placebo ALZT-OP1b", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AZTherapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "55 Years to 79 Years" }, "enrollment_count": 620, "start_date": "2015-09-15", "completion_date": "2020-11-18", "has_results": false, "last_update_posted_date": "2021-11-10", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 69, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02547818" }, { "nct_id": "NCT04937959", "title": "Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease", "Alzheimer's Disease (Incl Subtypes)", "Preclinical Alzheimer's Disease", "Prodromal Alzheimer's Disease", "Mild Cognitive Impairment", "Normal Cognition" ], "interventions": [], "intervention_types": [], "sponsor": "Novoic Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 40, "start_date": "2021-01-22", "completion_date": "2022-08-30", "has_results": false, "last_update_posted_date": "2022-04-07", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 1, "location_summary": "Santa Ana, California", "locations": [ { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04937959" }, { "nct_id": "NCT01677572", "title": "Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 197, "start_date": "2012-10-05", "completion_date": "2019-07-31", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 32, "location_summary": "Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677572" }, { "nct_id": "NCT04592341", "title": "A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 192, "start_date": "2020-11-18", "completion_date": "2023-03-15", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 7, "location_summary": "Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more", "locations": [ { "city": "Atlantis", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Wellington", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592341" }, { "nct_id": "NCT01224106", "title": "A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 799, "start_date": "2010-11-30", "completion_date": "2020-09-10", "has_results": true, "last_update_posted_date": "2021-12-13", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 24, "location_summary": "Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01224106" }, { "nct_id": "NCT02640092", "title": "Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "[18F]GTP1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 72, "start_date": "2015-12-23", "completion_date": "2019-06-11", "has_results": false, "last_update_posted_date": "2019-12-23", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02640092" }, { "nct_id": "NCT04804241", "title": "Senicapoc in Alzheimer's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild Cognitive Impairment", "Alzheimer Disease" ], "interventions": [ { "name": "Senicapoc", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 55, "start_date": "2022-03-18", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 2, "location_summary": "Sacramento, California • Walnut Creek, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04804241" }, { "nct_id": "NCT05462106", "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyloid Plaque", "Beta-Amyloid", "DSAD", "Prodromal Alzheimer's Disease", "Alzheimer's Disease" ], "interventions": [ { "name": "Placebo (Study Part 1a)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 2)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 2", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 1b)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AC Immune SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 304, "start_date": "2022-06-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-26T08:15:20.259Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "The Villages", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462106" } ] }